Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Medicenna Therapeutics Corp

MDNA.TO ✓ COMPLIANT ☆ Track — members

TSX · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: BUY

Last Close

$0.34

▲ +2.17%

Market Cap $31.34M · Vol 33.85K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$31.34M

Micro Cap

Div Yield

N/A

EPS Growth

-63.81%

YoY

RSI (14)

53.13

Momentum

Beta

2.04

vs Market

52W High

$1.43

76.40% below

52W Low

$0.24

39.94% above

Volume

33.85K

Avg 48.45K

P/B

21.51

Price-to-book

ROE

-170.64%

Return on equity

Free Float

80.49%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Medicenna Therapeutics Corp (MDNA.TO) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MDNA.TO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.17%

+30.56%

+3.30%

-45.98%

YTD

-48.91%

-54.81%

-9.16%

-84.33%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-13,230,559.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-170.64%
ROA · ROIC	-99.95% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	21.51
P/FCF	N/A
EPS Growth	-63.81%
Outstanding Shares	92.30M

Technical Indicators

50-Day SMA	$0.29
200-Day SMA	$0.52
RSI (14)	53.13
Beta	2.04
52-Week High	$1.43
52-Week Low	$0.24

Volume Today	33.85K
Avg Daily Volume (30D)	48.45K
Relative Volume	0.70x
Volatility (10D)	51.52
Volatility (30D)	60.46
Free Float	80.49%

Analyst Consensus

BUY

Current Price $0.34

Mean Target $2.43

52W Low$0.24 52W High$1.43

Current

Target

$0.24 $1.43

Current Analyst target

+612.64% upside potential · 3 analysts

Identifiers

ExchangeTSX

FIGIBBG008MPLP12

ISINCA58490H1073

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.77% ARGX.BR argenx SE +1.31% ARGX argenx SE -0.18% INSM Insmed Inc +0.04% 2269.HK WuXi Biologics (Cayman) Inc +2.97%

Company Profile

Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.